• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·301207.SZ
Share

Hualan Biological Vaccine Inc. Stocks

CN¥ 16.97Last Updated 10.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.50B

CN¥ 16.97
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on the entire vaccine lifecycle, from research and development to manufacturing and sales within China. The company's product line features a diverse range of immunizations, including various influenza virus vaccines (such as split, quadrivalent, and H1N1 strains), recombinant hepatitis B vaccines, and meningococcal polysaccharide vaccines (including ACYW135 and Group A & C types). They also develop genetically engineered vaccines for human use. Established in 2005, Hualan Biological Bacterin Inc. is headquartered in Xinxiang, China, and previously operated as a subsidiary of Hualan Biological Engineering Inc.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 301207.SZ is 25.7 and suggests 51.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.07.2026 21:00

SK Hynix's Debut, Shein's New Plan, and Logistics Companies from Uzbekistan: Key IPO Updates as of July 12

12.07.2026 18:01

"Buffett in a Skirt": How Hetty Green Built an Empire on Crises and Saved Wall Street

12.07.2026 15:01

"The 30-Second Rule": How Investors Can Learn to Think Things Through Before Making Trades

12.07.2026 05:26

The U.S. announced a third wave of strikes against Iran following the closure of the Strait of Hormuz

11.07.2026 19:01

A Triumph for City Governments? How China’s Scaling Model Will Change the Global AI Market

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026